Can a Two-Pronged pill outsmart stubborn leukemia?
Disease control
Recruiting now
This early-stage trial is testing an experimental oral drug, HPB-092, in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The drug is designed to block two proteins, FLT3 and IRAK4, that help leukemia cells grow and survive. The stud…
Phase: PHASE1 • Sponsor: Hangzhou Polymed Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC